Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Payables (2018 - 2025)

Dna X filings provide 8 years of Payables readings, the most recent being $9.1 million for Q4 2025.

  • On a quarterly basis, Payables rose 1132.38% to $9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 1132.38% increase, with the full-year FY2025 number at $9.1 million, up 1132.38% from a year prior.
  • Payables hit $9.1 million in Q4 2025 for Dna X, down from $20.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $23.5 million in Q2 2025 to a low of $738000.0 in Q4 2024.
  • Median Payables over the past 5 years was $13.0 million (2021), compared with a mean of $14.5 million.
  • Biggest five-year swings in Payables: crashed 96.28% in 2024 and later soared 1132.38% in 2025.
  • Dna X's Payables stood at $9.5 million in 2021, then surged by 123.01% to $21.1 million in 2022, then decreased by 6.05% to $19.8 million in 2023, then crashed by 96.28% to $738000.0 in 2024, then soared by 1132.38% to $9.1 million in 2025.
  • The last three reported values for Payables were $9.1 million (Q4 2025), $20.8 million (Q3 2025), and $23.5 million (Q2 2025) per Business Quant data.